Tianda Pharmaceuticals (HKSE:00455) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:00455 Tianda Pharmaceuticals Ltd HKSE:00455
24 GF Score
Price HK$0.11
GF Value HK$0.13
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Tianda Pharmaceuticals FFO?

FFO (Funds from operations) only applies to REITs.

HKSE:00455
24GF Score
Tianda Pharmaceuticals Ltd HKSE:00455
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Tianda Pharmaceuticals (HKSE:00455) Overvalued in 2026?

Based on GuruFocus' analysis, Tianda Pharmaceuticals stock appears to be undervalued. The current stock price of HK$0.11 is trading 14.6% below its estimated GF Value™ of HK$0.13. GuruFocus considers Tianda Pharmaceuticals to be Modestly Undervalued.

Key valuation signals for HKSE:00455:

  • FFO:
  • GF Value™: HK$0.13 vs. price of HK$0.11 (14.6% below fair value)
  • GF Score™: 24/100 with 3 warning signs

No single metric tells the full story. See the HKSE:00455 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Tianda Pharmaceuticals Business Description

Address No. 1 Tim Mei Avenue, Suites 2405-2410, 24th Floor, CITIC Tower, Central, Hong Kong, HKG
Tianda Pharmaceuticals Ltd is engaged in research and development, manufacturing, and sales of pharmaceutical, biotechnology, and healthcare products, and investment in the development of the Chinese medicine industry. The group also engages in research and development of Chinese medicine, sales of Chinese herbal medicines, traditional Chinese medicine decoction pieces and Chinese medicine, and provision of Chinese medicine clinical services. Its operating segments include the Chinese medicine business; Medical and healthcare services; and Pharmaceuticals and medical technologies business. The company derives the majority of its revenue from the Pharmaceuticals and medical technologies business. Its geographical segments include Mainland China, Hong Kong, and Australia.
24GF Score

Get the complete analysis for HKSE:00455

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$0.11
Price
HK$0.13
GF Value